Dosing facts, in brief
- No approved dose exists. Retatrutide is investigational; every published human dose comes from a supervised clinical trial.
- Trials used 0.5–12 mg once weekly, always starting low (1–4 mg) and escalating no faster than every four weeks. 12 mg weekly is the highest dose ever studied in humans.
- The half-life is about six days: levels accumulate for roughly a month after any change and plateau near double a single dose. Effects lag dose changes by weeks.
- Syringe units measure volume, not milligrams — the mg-per-unit depends entirely on vial size and diluent volume, which is why copied unit counts cause large overdoses.
- This page is educational safety context for an unapproved compound supplied for laboratory research. It is not medical advice and not a usage protocol.
Why there is no official dosing guideline
Approved medicines carry prescribing information because a regulator has reviewed the complete evidence and defined a dose where benefit justifies risk. Retatrutide has not been through that process anywhere in the world. Until it is licensed, the phrase “recommended dose” has no regulatory meaning for this compound — anyone stating one is either quoting the trial protocols or making it up.
What does exist is unusually consistent: every arm of every published trial used once-weekly subcutaneous administration, a deliberately low starting dose, and escalation steps of at least four weeks. That design was not cautious box-ticking — it is what kept the gastrointestinal side-effect burden tolerable, and the arms that started higher tolerated treatment measurably worse.
The dosing used in the clinical trials
Phase 2 · Obesity · NEJM 2023
Jastreboff et al. randomised 338 adults to once-weekly subcutaneous retatrutide at 1, 4, 8, or 12 mg, or placebo, for 48 weeks. Nobody started at their target dose: the higher arms began at 2 mg or 4 mg and stepped up no faster than every four weeks. The 12 mg arm started at 2 mg — a six-fold escalation spread across months.
Phase 2 · Type 2 diabetes · Lancet 2023
Rosenstock et al. studied 0.5, 4, 8, and 12 mg weekly in adults with type 2 diabetes, again with slow stepped escalation. Gastrointestinal side effects tracked the starting dose and the escalation speed, not just the final dose — the arms that began at 2 mg tolerated treatment measurably better than those that began at 4 mg.
Phase 3 · TRIUMPH programme · 2026
The pivotal Phase 3 trials kept the same once-weekly, slow-titration design at up to 12 mg. Across the entire clinical programme — thousands of participants — 12 mg once weekly remains the highest dose ever given to humans. There is no human safety data of any kind above it.
Full results, including the reported outcomes at each dose, are summarised in our overview of the clinical trial evidence, with primary sources and DOIs in the research library.
What the published escalation looked like
For concreteness, this is the stepped escalation the Phase 2 trial’s highest arm followed to reach its target dose (Jastreboff et al., NEJM 2023) — reproduced here as published trial data, not as a schedule to follow:
| Trial weeks | Once-weekly dose | Step |
|---|---|---|
| 1–4 | 2 mg | Deliberately low start — a sixth of the target |
| 5–8 | 4 mg | Doubled only after four full weeks |
| 9–12 | 8 mg | Doubled again — still below target at three months |
| 13 onwards | 12 mg | Target reached in month four; the highest dose ever studied |
The shape is the message: a supervised trial took a quarter of a year to reach its own maximum, under investigator monitoring, in a screened population. Lower-dose arms started at 1–4 mg on the same four-week rhythm, and tolerability was measurably better in arms that started lower. Grey-market schedules that reach 12 mg in weeks — or pass it — have no relationship to any of this data.
Above 12 mg per week, the map ends
Within the studied range, adverse events scaled with dose — more nausea, more vomiting, a larger rise in resting heart rate. Above 12 mg weekly there is no human data at all: not on efficacy, not on the heart-rate effect, not on anything. Because levels accumulate for about a month, someone escalating past the studied range does not discover their mistake at injection time — they discover it weeks later, with several doses already on board and a six-day half-life between them and lower levels. See side effects, including at higher doses for what is known about how risk scales.
The errors behind most accidental overdoses
Treating syringe "units" as a dose
An insulin syringe measures volume, not mass: on a U-100 syringe, 10 units is 0.1 ml of whatever concentration is in the vial. A 10 mg vial reconstituted with 1 ml of water gives 1 mg per 10 units; the same vial reconstituted with 2 ml gives 0.5 mg per 10 units. Copying someone else’s unit count without knowing their vial size and diluent volume is the single most common way people end up on several times the amount they intended. Pre-mixed pens remove this error class — their concentration is fixed at manufacture and printed on the specification — but concentrations differ between brands and strengths, so a volume habit learned on one product silently misdoses on another. Our reconstitution calculator does this arithmetic from your own numbers, or from a stated concentration, and flags implausible results.
Escalating too fast, or stacking doses
Retatrutide’s half-life is roughly six days, so a weekly schedule accumulates: levels keep building for about a month after any change and plateau at close to double a single dose. A dose taken today is not felt in full for weeks. Increasing the dose because "nothing is happening" in week one — or re-dosing early — puts levels far above anything studied, and the trials escalated no faster than four-week steps for exactly this reason.
Restarting at full dose after a break
Tolerance to the gastrointestinal effects builds at a given level and fades within a few weeks off. Prescribing information across the approved GLP-1 class tells patients to drop back down and re-titrate after missed weeks; someone returning to their old dose after a month away is effectively dose-naive at that level.
Assuming the label is accurate
All of the arithmetic above assumes the vial contains what it claims. Independent testing of grey-market peptide vials has found significant under- and over-dosing. Without a batch-matched, independently verifiable Certificate of Analysis, no dose calculation is meaningful.
Frequently asked questions
What is the correct dose of retatrutide?
There is no correct dose, because there is no approved dose. Retatrutide is an investigational compound: it has no licence, no prescribing information, and no established human dosing outside clinical trials. The trials themselves used once-weekly subcutaneous doses between 0.5 mg and 12 mg, always beginning at 1–4 mg and escalating no faster than every four weeks. That is trial data, not a recommendation — RETApro supplies retatrutide for laboratory research only.
What doses were used in the retatrutide clinical trials?
The Phase 2 obesity trial (NEJM, 2023) used 1, 4, 8, and 12 mg once weekly, with the higher arms starting at 2–4 mg and stepping up every four weeks or slower. The Phase 2 diabetes trial (Lancet, 2023) used 0.5–12 mg on the same pattern, and the Phase 3 TRIUMPH programme kept the once-weekly slow-titration design at up to 12 mg. 12 mg once weekly is the highest dose ever studied in humans.
Is a higher dose of retatrutide more effective?
In the trials, higher doses produced larger metabolic effects — and proportionally more adverse events. That relationship was only characterised up to 12 mg weekly. Above that there is no efficacy data and no safety data, so a higher dose buys unquantified risk for unproven benefit. Side effects, including the dose-dependent rise in resting heart rate, scaled with dose throughout the studied range.
How many units of retatrutide is 1 mg?
It depends entirely on how the vial was reconstituted, which is why the question has no fixed answer. Syringe units measure volume: on a U-100 insulin syringe, 100 units = 1 ml. A 10 mg vial reconstituted with 1 ml contains 10 mg/ml, so 1 mg occupies 10 units; the same vial with 2 ml of diluent gives 5 mg/ml, so 1 mg occupies 20 units. Unit counts copied from other people, who used different vials and volumes, are the most common source of large dosing errors.
How long does retatrutide stay in the body?
Its elimination half-life is around six days, which is what makes once-weekly dosing possible. Practically, that means levels build for roughly four weeks after starting or changing a dose before they plateau, and meaningful amounts remain in the body for several weeks after the last dose. Effects — including side effects — do not switch off when injections stop.